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The present study aimed to analyze outcomes of hypofractionated stereotactic radiotherapy 
(HFSRT) delivered in five fractions to metastatic brain tumors. Between June 2008 and June 2011, 
39 consecutive patients with 46 brain metastases underwent HFSRT at Kyoto University Hospital. 
Selection criteria included high risk factors such as eloquent location, history of whole-brain 
radiotherapy (WBRT), or large tumor size. Given these factors, fractionated schedules were 
preferable in terms of radiobiology. The prescribed dose at the isocenter was basically 35 Gy in five 
fractions. Brainstem lesions with a history of WBRT were treated with 20–25 Gy in five fractions. 
Planning target volume was covered by the 80% isodose line of the prescribed dose to the isocenter. 
Local-control probability and overall survival were estimated using the Kaplan–Meier method. For 
the analysis of local control, the response criteria were defined as follows: complete response (CR) 
was defined as no visible gross tumor or absence of contrast enhancement, partial response (PR) as 
more than a 30% decrease in size, progressive disease (PD) as more than a 20% increase in size, and 
stable disease (SD) as all other responses. Local control was defined as a status of CR, PR, or SD. 
Only patients with at least 3 months or longer follow-up (21 patients, 27 tumors) were included in 
the analysis. Median age and Karnofsky performance status were 59 years (range, 39–84 years) and 
90 (range, 40–100), respectively. Tumor volumes and maximum diameters ranged from 0.08 to 
15.38 cc (median, 3.67 cc) and from 3 to 34 mm (median, 18 mm), respectively. The median 
follow-up period was 329 days (range, 120–1321 days). Local-control probabilities at 6 and 12 
months were 92.1% and 86.7%, respectively. Overall survival after HFSRT at 6 and 12 months was 
85.4% and 64.5%, respectively. Grade 3 radiation necrosis was observed in one patient according to 
the Common Terminology Criteria for Adverse Events version 3.0. The patient was successfully 
managed conservatively. HFSRT for metastatic brain tumors yields high local-control probabilities 




Brain metastases are a commonly reported condition, occurring in 20–40% of patients with cancer 
[1]. Brain metastases may be symptomatic and can be the direct cause of death. Brain metastases are 
primarily treated with open surgery and radiotherapy. Radiotherapy strategies include whole-brain 
radiotherapy (WBRT) and/or stereotactic irradiation, depending on the clinical situation [2 6]. 
Stereotactic radiosurgery (SRS) yields high local-control rates for relatively small lesions. 
However, local control using a single-fraction dose becomes difficult as tumor size increases. 
Large tumors required a high dose for local control, and exposure of normal brain tissue to a high 
radiation dose increases the probability of late toxicities such as radiation necrosis [7]. 
Furthermore, lesions with a history of WBRT and those located in an eloquent area such as 
brainstem can increase the probability of the toxicity because normal brain tissue in these cases 
probably have a lower tolerance for irradiation and late toxicities should be more problematic in 
eloquent areas than non-eloquent areas [8]. Survival rates have increased as systemic therapies have 
improved [1]. More attention should be given to late toxicities under these conditions. 
Hypofractionated stereotactic radiotherapy (HFSRT) may provide a way to maintain high 
local-control rates without increasing late toxicities [9,10]. Recent advances in precision and the 
development of a less invasive fixation technique have increased the safety of irradiation using a 
fractionated schedule. The present paper reports the outcome of HFSRT treatment for metastatic 
brain tumors.
4 
Materials and methods 
 
Patients and tumor characteristics 
 
From June 2008 through July 2011, 39 consecutive patients with 46 brain metastases underwent 
HFSRT at Kyoto University Hospital. Inclusion criteria included high risk factors such as lesions in 
eloquent locations, prior history of WBRT, and large tumors (maximum diameter >15 mm). 
Eloquent lesions are defined as those located at or adjacent to the brainstem, basal ganglion, or 
motor areas. Of 39 patients, 21 with 27 lesions had follow-up magnetic resonance imaging (MRI) 
scans at least once 3 months or more after HFSRT and were included in the analysis. The remaining 
18 patients could not undergo follow-up MRI scans because of poor performance status. Eligible 
patient and tumor characteristics are summarized in Table 1. According to the Radiation Therapy 
Oncology Group (RTOG) recursive partitioning analysis (RPA) [11], the majority of patients in our 




The treatment was performed using the Novalis system equipped with the ExacTrac system ver. 
5.02 and Robotic Tilt Module mounted on the Exact Couch top (BrainLAB AG, Feldkirchen, 
Germany). Patients were immobilized in a thermoplastic stereotactic head mask with an additional 
bite block and infrared reflecting markers (BrainLAB AG). Computerized tomography (CT) images 
of 1.25-mm slice thickness were acquired using a Light Speed RT scanner (GE Healthcare, 
Milwaukee, WI, USA). Contrast-enhanced MRI scans were also referred with CT-MRI fusion 
devices. The gross tumor volume (GTV) was defined as the contrast-enhanced lesion detected in 
CT/MRI images. The clinical target volume (CTV) was defined as being identical to the GTV. The 
planning target volume (PTV) was formed by expanding the CTV with a 1-mm margin. This margin 
was evaluated using upfront analysis of the geometric accuracy of frameless stereotactic 
radiotherapy systems in our hospital [12]. All lesions were treated using a dynamic conformal arc 
technique with multileaf collimator (MLC) margin 0–1 mm, planned with iPlan RT Dose 4.1.2 
(BrainLAB AG). Three or four arc beams were used. Patients were positioned using the 
Novalis/ExacTrac system. Positional errors including translations and rotations were corrected by 
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moving the robotic couch. The prescribed doses were specified at the isocenter, and 35 Gy in five 
fractions was basically prescribed. Brainstem lesions with a prior history of WBRT were treated 
with lower doses: 20–25 Gy in five fractions was prescribed. PTV was covered by the 80% isodose 
line of the prescribed dose to the isocenter. One lesion was exceptionally treated with 40 Gy in five 
fractions at the discretion of the treating physician. 
 
Follow-up and analysis 
 
After treatment, patients underwent a follow-up MRI scan every 1–3 months, and the maximum 
diameter of the irradiated lesion in the axial image was measured. Twenty-one patients with 27 
lesions had follow-up MRI scans at least once 3 months or more after HFSRT and were eligible 
for the analysis of local-control probability, probability of developing new brain metastases, 
overall survival, and time to neurological deterioration in the present study. For the analysis of 
local control, the response criteria were defined as follows: complete response (CR) was defined as 
no visible gross tumor or absence of contrast enhancement, partial response (PR) as more than a 
30% decrease in size, progressive disease (PD) as more than a 20% increase in size, and stable 
disease (SD) as all other responses. Local control was defined as a status of CR, PR, or SD. 
Radiation necrosis/injury was defined as lesions in which the contrast-enhanced MRI images were 
enhanced peripherally or heterogeneously and resulted in no continuous progression on further 
follow-up. A nuclear medicine study such as positron-emission tomography was conducted as 
necessary. Open surgery and pathological diagnosis was recommended for lesions that caused 
clinical symptoms and could not be controlled conservatively. Radiation necrosis was not included 
in the PD category in the analysis of local control.  
Neurologic deterioration was defined a decline in the KPS of ≥30 for at least 1 week or 
a decline in KPS from any baseline to ≤50 for at least 1 week. If the KPS before HFSRT was <70, 
neurologic deterioration was defined as any decline in the KPS after HFSRT for at least 1 week. A 
temporal decline in KPS that was attributable to other causes and not to a neurologic deficit was 
excluded. The cause of death was considered a neurologic cause if the patient had progressive 





Local-control probability, probability of developing new brain metastases, and overall survival 
were calculated using the Kaplan–Meier method. The local control probability and the probability 
of developing new brain metastases were evaluated from the initial HFSRT treatment to the date of 
failure or last imaging follow-up. Overall survival was measured from the initial HFSRT to the date 
of death or last follow-up. Time to neurological deterioration was measured from the date of the 




Local control and new lesion development 
 
The median duration of imaging follow-up was 286 days (range, 92–1315 days). PTV and 
maximum diameter of the tumor ranged from 0.08 to 15.38 cc (median, 3.67 cc) and from 3 to 34 
mm (median, 18 mm), respectively. With the exception of the brainstem lesions (5 lesions, 18.5%), 
the PTV and maximum diameter were 0.44–15.38 cc (median, 5.44 cc) and 9–34 mm (median, 23 
mm), respectively. Brainstem lesions are more likely to be symptomatic and lethal than lesions in 
other locations, even when they are relatively small [13]; thus, we treated the brainstem lesions as 
soon as possible. Of the 21 patients, 10 (47.6%) with 15 of the 27 lesions (55.6%) had a history of 
WBRT before receiving HFSRT. The time between the end of prior WBRT and the initiation of 
HFSRT was 563 days (69 1116 days). The dose fractionation of prior WBRT was 30 Gy in 10 
fractions (seven patients), 37.5 Gy in 15 fractions (two patients), and 25 Gy in 10 fractions (one 
patient). All these patients underwent HFSRT as salvage for failed WBRT. 
The local-control probabilities were 92.1% (95% confidence interval [CI], 82.2–100) at 
6 months and 86.7% (95% CI, 73.5–100) at 12 months (Fig. 1a). At the time of analysis, four 
lesions in four patients were diagnosed as PD (Table 1). All PD lesions had been treated with an 
irradiation schedule of 35 Gy in five fractions.  
Eleven patients (52.4%) had new brain metastases after the initial HFSRT treatment. 
The probability of developing new brain metastases was 45.4% (95% CI, 18.1–63.6) at 6 months 




According to the CTCAE version 3.0, no grade 3–4 acute toxicities occurred in our study. Two 
grade 2 seizures were observed: one transient partial convulsion and one general seizure. Grade 2 
mild hemorrhages at the irradiated site were observed in three patients, and they were successfully 
managed conservatively. We observed late toxicity in one patient, who developed a grade 3 
radiation necrosis associated with clinical symptoms. The patient had a metastatic tumor in the right 
frontal lobe derived from breast cancer. The tumor was treated with 40 Gy in five fractions. The 
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patient had a history of WBRT (30 Gy in 10 fractions) performed 15 months prior to the HFSRT. 
Initially, the tumor appeared to gradually shrink, but the contrast-enhanced lesion emerged 
approximately 2 years after HFSRT with clinical symptoms, increased weakness, and gait 
impairment. Surgery was recommended by a specialized neurosurgeon, but the patient refused and 
was treated with conservative therapy. At present, the symptoms have improved, and the enhanced 
areas and surrounding edema have disappeared. 
 
Overall survival and time to neurological deterioration 
 
The median follow-up after HFSRT was 329 days (range, 120–1321 days). Overall survival was 
85.4% (95% CI, 71.5–100) at 6 months and 64.5% (95% CI, 46.3–89.8) at 12 months (Fig. 1c). 
Time to neurological deterioration was a median of 316 days (range, 98 1011 days). 
Nine patients had died at the time of analysis. The cause of death was neurologic causes 
in four patients and progressive systemic cancer in five patients. Another three patients were lost 
to follow-up, and all had progressive intracranial diseases and neurologic dysfunction. The 
remaining nine patients are alive to date and all except one is free from neurologic symptoms. The 
one patient had neurologic deterioration due to progressive intracranial disease. 
   As to the seven patients with eight eloquent lesions, time to neurological 
deterioration was a median of 231 days (range, 98–651 days) after the initiation of HFSRT. Of 
them, four patients had one or two lesion(s) at the brainstem and three patients had a history of 
WBRT (30 Gy in 10 fractions). The intervals between the end of WBRT and the initiation of 
HFSRT were 69, 171, and 325 days. Three improved or had stable neurologic symptoms at the 
time of last follow-up: two had stable or improved oculomotor nerve impairment and one had no 
neurologic symptoms. The other had local brainstem failure at 434 days after HFSRT and also had 
rapidly growing multiple intracranial lesions that caused neurologic deterioration. In contrast, two 
of three patients with lesions at the motor area had no severe acute toxicity but had neurologic 





Research in the 1990s suggested that hypofractionation had significant benefits over single-dose 
radiosurgery in terms of widening the therapeutic window between tumor control and late effects, 
particularly for malignant tumors [9,10]. Current noninvasive, sophisticated techniques such as 
HFSRT have enabled clinicians to deliver high radiation doses to lesions precisely and repeatedly.  
Dose escalation using single-fraction radiosurgery is problematic because large tumors 
require high doses that may cause late neurological toxicities. The first dose-escalation study using 
single-fraction radiosurgery (Radiation Therapy Oncology Group Study 90-05; RTOG 90-05) [7] 
was conducted to establish the maximum tolerable dose for patients with recurrent, previously 
irradiated, primary brain tumors and brain metastases. Doses were prescribed to the 50–90% 
isodose line according to the maximum diameter of the tumor. The results showed that the 
maximum tolerable doses for SRS were 24 Gy, 18 Gy, and 15 Gy for tumors with maximum 
diameters ≤20 mm, 21–30 mm, and 31–40 mm, respectively. Thus, the dose for larger tumors was 
reduced when using single-dose SRS, although dose escalation would be desirable in terms of 
controlling larger tumors. 
In daily clinical practice, lesions amenable to SRS are typically <3 cm in maximum 
diameter [14], and local control has been reported to be influenced by tumor size [15 18]. 
However, the relationship between tumor size and local control is difficult to assess because lower 
doses are prescribed for larger tumors and higher doses for smaller ones. Thus, the relationship 
between tumor size and local control in relation to one fixed dose in a single fraction is not clear 
and is seldom addressed in the literature. For relatively small tumors ≤2 cm, many reports have 
shown good local control rates by using single-fraction SRS [14]. However, a cut-off value for 
local control seems to exist in even small tumors ≤2 cm. To our knowledge, there are two reports 
regarding this point of view [19,20]. One study by Chang et al. [19] showed that the threshold 
value was a maximum tumor diameter of 1 cm. The maximum diameter of the treated lesions in 
that study was 2.1 cm, and they were treated in a single fraction with a prescribed dose of 20–24 
Gy to the periphery of the target. Chang and colleagues reported that the 1-year local-control rates 
were 86% in tumors with a diameter ≤1 cm and 56% in tumors with a diameter >1 cm [19]. The 
local-control rates found in the larger-diameter group were low compared with previously reported 
rates [14], which may have been due to the authors’ criteria for inclusion and local treatment 
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failure. The other study by Shehata et al. [20] reported excellent local control with single-fraction 
SRS for ≤2 cm tumors. At the same time, they also found that tumor volume was a significant 
factor affecting tumor control in their multivariate analysis. The threshold value was 0.3 cc, which 
was equal to about 0.8 cm estimated diameter. 
Evidence suggests that hypofractionation could overcome the disadvantages of 
single-fraction radiosurgery. Several investigators have reported good results for local control 
using various hypofractionation schedules [21 29]. We also achieved high local-control rates of 
92.1% and 86.7% at 6 and 12 months, respectively, despite relatively large tumor diameters 
(median, 18 mm), and four relapsed cases (Table 1), which were irradiated with 35 Gy in five 
fractions. Two of the tumors were derived from colon and renal cancers, which were thought to be 
radioresistant tumors. Additionally, all four patients with these lesions had uncontrolled 
extracranial lesions, and these unfavorable factors might be associated with undesirable outcomes, 
but the actual relationship between local control and its predictive factors was not clear in the 
present study. An increase in dose escalation may be necessary to obtain better local-control 
probabilities; however, our sample size was too small to confirm this notion.  
Optimal fractionation schedules need to be determined. Wiggernraad et al. [29] conducted 
a systematic review of stereotactic fractionated radiotherapy in metastatic brain tumors using a 
modified linear–quadratic–cubic (LQC) model. The LQC model adjusted the LQ model to account 
for a more linear response at higher doses by adding an additional term proportional to the cube of 
the dose. They concluded that a biologically effective dose at an /  value of 12 Gy (BED12) of at 
least 40 Gy was needed for a 12-month local-control rate of 70% or greater. Most of the patients in 
our study received a dose of 35 Gy in five fractions. Using a classical LQ model, the BED12 of this 
dose fractionation is significantly lower than that of single dose fraction radiosurgery. For 
example, the BED12 of 25 Gy in a single fraction is 77.1 Gy according to the classical LQ model, 
and 35 Gy in five fractions corresponds to a BED12 of 55.4 Gy. However, using the LQC model, 
both dose fractionations are the same, estimated as BED12 = 53.0 Gy. The peripheral doses of PTV, 
80% of the prescribed dose at the isocenter, were 28 Gy in five fractions and 20 Gy in a single 
fraction. Both were calculated as a BED12 of 40 Gy. Thus, we obtained good local-control rates in 
our study, supporting the notion of a more linear response rate between cell survival and dose at 
higher doses. Application of the LQC model to clinical practice is reasonable when comparing the 
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BED12 of HFSRT with that of SRS at high doses. Lower doses estimated using the classical LQ 
model should provide good local control of metastatic brain tumors despite large sizes. 
The role of tumor size in the control of brain metastases was not clear in the present 
study. Aoyama et al. [23] reported tumor volume >3 cc (equal to about 1.8 cm estimated diameter) 
is a significant prognostic factor for local control. However, some aspects of their study were 
different from ours as follows: a fractionation schedule of 20–40 Gy in four fractions at the 
isocenter, setup accuracy and PTV margin of 2 mm, and dose delivery without MLC. To our 
knowledge, no other study has described the relationship between tumor size and local control in 
HFSRT. We think that the rationale behind better local control in HFSRT is safe dose escalation 
for larger tumors and radiobiological benefit of fractionation. According to the LQC model, 
HFSRT enables deliver of the same effective doses for larger tumors as a high-single dose for 
smaller tumors. In addition, some radiobiological benefit, such as reoxygenation, also contributes 
to better outcomes. The interval between each fractionated dose allows hypoxic tumor cells to be 
aerobic and radiosensitive, and to be killed by subsequent dose fractions [10]. The maximum 
diameter in the present study was up to 34 mm. Tumors within this range seem to be safely 
controlled and a cutoff may exist at much larger sizes. However, HFSRT for much larger tumors 
would be a remaining issue for the future evaluations. 
Late toxicities such as radiation necrosis and radiation injury may be life-threatening. The 
exact rates of radiation necrosis are not known. One reason for this is the difficulty in differentiating 
between a radiation injury and a recurrence [30]. Few studies describe the method used to 
distinguish a radiation necrosis from a true recurrence in their analysis of local control in brain 
metastases. The judgment appears to be based on clinical factors in most studies, and many report 
crude rates of radiation necrosis of 5–10% [29]. In the RTOG 90-05 study, radiation necrosis was 
frequently observed when large-volume tumors were irradiated with high doses that were not 
clinically tolerated. In our study, the crude rate of radiation necrosis was 3.7% (one lesion), which 
occurred in the lesion irradiated with a dose of 40 Gy in five fractions. This patient had a history of 
WBRT, 30 Gy in 10 fractions. Radiation necrosis was not observed in other lesions in our study in 
those treated with 20–35 Gy in five fractions, even though half of them had been previously 
irradiated with WBRT. Moreover, with the exception of lesions in the brainstem, the median PTV 
was relatively large (median 5.44 cc); however, we did not observe severe toxicity. 
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To our knowledge, no reports have shown a direct comparison of the incidence of 
radiation necrosis between WBRT plus SRS and SRS alone. However, we have some suggestive 
data in the Japanese randomized controlled trial [5]. In this trial, 132 patients with one to four 
metastases, each less than 3 cm in diameter, were randomly assigned to receive up-front WBRT 
plus SRS (65 patients) or SRS alone (67 patients). As a result, more patients treated with SRS plus 
WBRT developed radiation necrosis (three patients) than patients treated with SRS alone (one 
patient), although the SRS dose was reduced by 30% in SRS plus WBRT group compared with 
SRS alone group. This observation suggests WBRT followed by SRS may result in increasing the 
risk of radiation necrosis. 
A reduction in late toxicity is crucial for long-term survival. Patients with primary tumors 
such as renal cancer have been reported to have longer survival times than patients with other 
primary tumors [22], and more investigations should focus on the longer-surviving patients. 
Varlotto et al. [31] reported that the actuarial incidence of adverse events at 1 and 5 years was 2.8% 
and 11.4%, respectively, in patients who had survived at least 1 year after radiosurgery for brain 
metastases. In our study, nine patients survived more than 1 year after HFSRT. One patient, who 
was treated with 40 Gy in five fractions, developed radiation necrosis. The sample size in our study 
was small, but 35 Gy in five fractions appears to be a safe dose. 
The small sample size in the present study and limitations imposed by retrospective 
analyses do not allow us to definitively state that metastatic tumor treatment with HFSRT is 
superior to SRS. However, a randomized trial to compare these two methods would be unethical 
considering the toxicity of the higher doses in SRS. Nonetheless, a prospective study to determine 
optimal dose and fractionation schedules is warranted. Our results demonstrate the potential of 
HFSRT in terms of tumor-control probability and reduction in toxicities as a treatment for 





We conclude that HFSRT is safe and produces high local-control rates for metastatic brain tumors 
with high risk factors. We will continue to use this fractionation schedule for these difficult cases 
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Fig. 1 a Local-control probability, b probability of developing new brain metastases, and c overall 
survival estimated using the Kaplan–Meier method 
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Table 1 Patient and tumor characteristics 
a This indicates the time between initiation of hypofractionated stereotactic radiotherapy and progression or last imaging follow-up. 
Abbreviations: C Controlled; CUP Cancer of unknown primary; F Female; fr fraction; HP Hypopharynx; KPS Karnofsky performance status; M Male; MD Maximum diameter; N Radiation necrosis; 




























1 61, M 70 II Lung Exist / active Yes Temporal No 23 5.98 7 C 95 Dead (systemic) 
2 46, F 80 II Breast Exist / inactive No Cerebellum No 28 7.11 7 C 404 Alive 
3 52, M 90 I CUP None No Temporal No 34 11.16 7 C 328 Lost to follow up 
4 66, M 80 II Lung Exist / active Yes Brainstem Yes 8 0.30 4 C 181 Dead (systemic) 
5 60, F 100 I Lung None Yes Parietal No 10 1.04 7 C 461 Alive 
6-1 57, F 100 II Breast Exist / inactive Yes Frontal No 28 11.40 8 N 1315 Alive 
6-2 58, F 80 II 
 
Exist / inactive Yes Cerebellum No 9 0.44 7 C 711 
 
7 54, M 100 I Lung None Yes Cerebellum No 31 10.08 7 C 526 Alive 
8 39, M 80 II HP Exist / inactive No Frontal Yes 28 9.78 7 C 138 Dead (systemic) 
9 49, F 100 II Lung Exist / active No Temporal No 16 2.70 7 R 187 Alive 
10-1 74, F 90 II Lung Exist / inactive Yes Parietal No 12 1.45 7 C 521 Alive 
10-2 74, F 90 II 
 
Exist / inactive Yes Brainstem Yes 8 0.44 5 C 521 
 
11-1 61, M 80 II Lung Exist / inactive Yes Temporal No 27 15.38 7 C 286 Dead (neurologic) 
11-2 61, M 80 II 
 
Exist / inactive Yes Parietal Yes 17 2.56 7 C 286 
 
11-3 62, M 70 II 
 
Exist / inactive Yes Temporal No 19 3.67 7 C 159 
 
12-1 84, F 40 III Kidney Exist / active No Brainstem Yes 3 0.08 7 C 434 Dead (neurologic) 
12-2 84, F 40 III 
 
Exist / active No Brainstem Yes 6 0.26 7 R 434 
 
13 54, F 80 II Lung Exist / active Yes Cerebellum No 28 5.79 7 C 92 Dead (systemic) 
14 59, F 90 II Breast Exist / active No Temporal No 18 5.08 7 C 229 Dead (systemic) 
15 71, M 100 II Lung Exist / inactive No Frontal No 16 2.49 7 C 715 Alive 
16 68, M 90 II Colon Exist / active No Parietal Yes 25 4.58 7 R 132 Lost to follow up 
17 68, M 100 II Lung Exist / inactive No Occipital No 23 7.13 7 C 280 Alive 
18 39, F 100 II Uterus Exist / active No Temporal No 28 6.28 7 C 154 Lost to follow up 
19-1 39, F 90 II Lung Exist / active Yes Frontal No 13 0.57 7 C 162 Dead (systemic) 
19-2 39, F 90 II 
 
Exist / active Yes Parietal No 16 2.05 7 R 92 
 
20 65, M 90 II Lung Exist / inactive No Frontal No 25 6.74 7 C 347 Alive 
21 53, M 80 II Lung Exist / active Yes Brainstem Yes 13 1.14 5 C 116 Dead (systemic) 
